Tigermed sells Target Group to subsidiary Frontage Holdings for RMB270m

Hangzhou Tigermed Consulting Co., Ltd. announced a voluntary share transfer agreement dated October 10, 2025, to dispose of the entire issued share capital of Teddy Clinical Research Laboratory (Shanghai) Ltd. to Frontage Laboratories (Shanghai) Co., Ltd. The total consideration for this intra-group transaction is RMB270,000,000. The Target Group, comprising the Target Company and its subsidiaries, will remain under the Company's umbrella following the disposal.

The consideration of RMB270,000,000 was determined through arm's length negotiations, referencing a valuation by Asia-Pacific Consulting and Appraisal Limited as of June 30, 2025. Frontage Holdings is also a subsidiary of Tigermed, with its shares listed on The Stock Exchange of Hong Kong Limited.

The board views this disposal as a strategic move to optimize resource allocation and enhance operational efficiency by integrating internal resources. It aims to promote synergies within the Group, centralize management, streamline decision-making, and improve cost efficiency and operational focus. The completion is contingent on Frontage Holdings obtaining independent shareholders' approval.